Apremilast (Otezla) is not recommended for treating moderate to severe chronic plaque psoriasis in adults whose psoriasis has not improved with other treatments, or they have had side effects with these treatments in the past or there is a reason why they cannot have them.
What does this mean for me?
Apremilast should not normally be prescribed on the NHS for chronic plaque psoriasis. Your doctor should talk to you about other treatment options available.
If you are already taking apremilast for chronic plaque psoriasis, you should be able to continue taking it until you and your doctor decide it is the right time to stop.
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.